New study seeks biomarkers to personalize radiation for nasopharyngeal cancer
NCT ID NCT07232680
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study enrolls 500 adults with nasopharyngeal carcinoma (stage I-III) who are receiving chemoradiotherapy with either proton or photon radiation. Researchers will collect imaging scans and blood samples to find markers that predict how well the cancer responds, side effects, and long-term outcomes. The goal is to better understand which patients benefit most from each type of radiation, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital at Linkou
RECRUITINGTaoyuan City, Taiwan, 333, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a baking soda rinse tame radiation mouth sores?
- New drug duo aims to keep advanced nasopharyngeal cancer in check
- Smart T-Cell engager aims to outsmart tumors in first human test
- New surveillance strategy aims to catch residual cancer early in High-Risk nasopharyngeal carcinoma
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment